Analysts Anticipate Zynex, Inc. (NASDAQ:ZYXI) Will Announce Quarterly Sales of $36.42 Million

Analysts forecast that Zynex, Inc. (NASDAQ:ZYXIGet Rating) will announce $36.42 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for Zynex’s earnings, with estimates ranging from $36.00 million to $36.76 million. Zynex reported sales of $31.02 million in the same quarter last year, which indicates a positive year-over-year growth rate of 17.4%. The company is expected to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Zynex will report full-year sales of $158.90 million for the current fiscal year, with estimates ranging from $156.17 million to $160.68 million. For the next fiscal year, analysts anticipate that the business will report sales of $193.95 million, with estimates ranging from $187.25 million to $201.60 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Zynex.

Zynex (NASDAQ:ZYXIGet Rating) last released its earnings results on Thursday, February 24th. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.04. Zynex had a net margin of 13.98% and a return on equity of 28.38%. The business had revenue of $40.37 million for the quarter, compared to analyst estimates of $41.06 million.

A number of research analysts have weighed in on ZYXI shares. Piper Sandler decreased their target price on shares of Zynex from $13.00 to $7.00 in a research note on Friday, February 25th. Zacks Investment Research lowered shares of Zynex from a “hold” rating to a “sell” rating in a research report on Saturday, April 30th. HC Wainwright reduced their price target on shares of Zynex from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, February 25th. Finally, B. Riley reduced their price target on shares of Zynex from $15.50 to $10.00 and set a “buy” rating on the stock in a research report on Monday, February 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Zynex currently has a consensus rating of “Hold” and a consensus price target of $14.70.

ZYXI opened at $7.11 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.67 and a quick ratio of 3.07. The company’s 50 day simple moving average is $6.60 and its two-hundred day simple moving average is $8.41. Zynex has a 1-year low of $4.97 and a 1-year high of $16.26. The firm has a market capitalization of $277.62 million, a price-to-earnings ratio of 14.59 and a beta of 0.87.

Hedge funds and other institutional investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. raised its position in Zynex by 1,213.7% in the first quarter. PNC Financial Services Group Inc. now owns 4,309 shares of the company’s stock valued at $28,000 after purchasing an additional 3,981 shares during the period. State of Tennessee Treasury Department raised its position in Zynex by 29.6% in the first quarter. State of Tennessee Treasury Department now owns 8,137 shares of the company’s stock valued at $51,000 after purchasing an additional 1,860 shares during the period. Nisa Investment Advisors LLC purchased a new stake in Zynex in the fourth quarter valued at approximately $63,000. Metropolitan Life Insurance Co NY purchased a new stake in Zynex in the third quarter valued at approximately $65,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new stake in Zynex in the first quarter valued at approximately $66,000. 28.06% of the stock is currently owned by institutional investors.

Zynex Company Profile (Get Rating)

Zynex, Inc, through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device.

Featured Stories

Get a free copy of the Zacks research report on Zynex (ZYXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zynex (NASDAQ:ZYXI)

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.